Kayne Bio Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-10-2024
- Paid Up Capital ₹ 0.50 M
as on 23-10-2024
- Company Age 5 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 0.41%
(FY 2023)
- Profit 40.19%
(FY 2023)
- Ebitda 85.03%
(FY 2023)
- Net Worth 243.38%
(FY 2023)
- Total Assets -9.73%
(FY 2023)
About Kayne Bio Sciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Alugadda Rao, Basava Reddy, and Meghana Alugadda serve as directors at the Company.
- CIN/LLPIN
U01114TG2019PLC132272
- Company No.
132272
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
24 Apr 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Kayne Bio Sciences Limited offer?
Kayne Bio Sciences Limited offers a wide range of products and services, including Cooking Spices and Masala, Seed Spices, Masala Powder, Dry Fruits & Nuts, Raisins, Cereals & Food Grains, Flours.
Who are the key members and board of directors at Kayne Bio Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Meghana Alugadda  | Director | 24-Apr-2019 | Current |
| Alugadda Rao | Director | 24-Apr-2019 | Current |
| Basava Reddy | Director | 24-Apr-2019 | Current |
Financial Performance of Kayne Bio Sciences.
Kayne Bio Sciences Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.41% increase. The company also saw a substantial improvement in profitability, with a 40.19% increase in profit. The company's net worth Soared by an impressive increase of 243.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kayne Bio Sciences?
In 2023, Kayne Bio Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Kayne Agri Estates Private LimitedActive 8 months 15 days
Basava Reddy and Meghana Alugadda are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kayne Bio Sciences?
Unlock and access historical data on people associated with Kayne Bio Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kayne Bio Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kayne Bio Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
